A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

NCT01995071 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C
Hepatitis C Virus
Compensated Cirrhosis

Interventions

DRUG: ABT-493
DRUG: ABT-530
DRUG: ABT-450/r/ABT-267, ABT-333
DRUG: Ribavirin (RBV)

Sponsor

AbbVie